MAP2K7 and melanoma: Interestingly, treatment with BRAF and MEK inhibitors associated with increased frequency of PD-1+ tumor cells in melanoma patients, and PD-1 expression sensitized melanoma to PD-1 blockade in immunodeficient mice (46).